We are building this new website to better deliver information. Find out more. We are building this new website to better deliver information. Find out more.
Let us know what you think.

Updates on 11/11/2020

Zoster (herpes zoster)

4.24.7 Recommendations

Addition of text reiterating importance of obtaining a medical history in patients prior to vaccination, to reiterate the contraindications regarding use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these individuals.

4.24.9 Contraindications

Addition of text and table to reiterate the contraindications regarding use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these individuals.

4.24.10 Precautions

Addition of text providing more specific detail of CD4 levels at which a person infected with HIV can receive zoster vaccine. (Refer also Chapter 3.3 Groups with special vaccination requirements).

4.24.11 Adverse events

Addition of text providing details of select serious outcomes where immunocompromised individuals have received zoster vaccine.

Zoster (herpes zoster)

Clarification of advice on the administration of live vaccines to patients receiving or planning treatment with biological and non-biological disease modifying anti-rheumatic drugs (DMARDs).

Removal of sub-section providing advice on the co-administration of zoster vaccine with other vaccines as information already provided earlier in chapter.

Zoster (herpes zoster)

4.24.6 Dosage and administration

Recommendations on the use of zoster vaccine updated, including: 

4.24.7 Recommendations

Recommendations on the use of zoster vaccine updated, including:

  • Zostavax recommendations now broken down by new age groups.